Inhibrx – Talk Bio

Actionable Insights Powered by AI

Sanofi gains AATD hopeful with $1.7-billion deal for Inhibrx

1 year ago talkbio0Tagged Acquisition (action), alpha 1-Antitrypsin Deficiency, Inhibrx, Market, sanofi

sanofi, Inhibrx, Acquisition (action), alpha 1-Antitrypsin Deficiency, Market